Top

Published in:

Open Access 01-12-2007 | Research

The median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancer

Authors: Paul A Blood, Tom Pickles

Published in: Radiation Oncology | Issue 1/2007

Abstract

Treatment guidelines recommend that curative radiation treatment of prostate cancer be offered only to men whose life expectancy is greater than 10 years. The average life expectancy of North American males is less than 10 years after age 75, yet many men older than 75 years receive curative radiation treatment for prostate cancer. This study used the provincial cancer registry in British Columbia, Canada, to determine median non-prostate cancer survival for men who were aged 75 to 82 years at start of radiation treatment. Median survival was found to be greater than 10 years in men aged up to 80 years at the start of their radiation treatment. This finding suggests that radiation oncologists are able to appropriately select elderly men with greater than average life expectancy to receive curative radiation treatment.

Available only for authorised users

Heidenreich A, Aus G, Abbou CC, Bolla M, Joniau S, Matveev V, Schmid HP, Zattoni F: European Association of Urology Guidelines on Prostate Cancer.In Edited by: Urology EA. [http://www.uroweb.org/fileadmin/user_upload/Guidelines/07_Prostate_Cancer_2007.pdf]

Statistics Canada: Statistics Canada. Life Tables, Canada, Provinces and Territories. 2000 to 2002. Life Tables, Canada, Provinces and Territories 2000 to 2002 [http://www.statcan.ca/english/freepub/84-537-XIE/tables.htm]

Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT: Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United States. J Natl Cancer Inst 2006,98(16):1134-1141.CrossRef

Band PR, Gaudette LA, Hill GB, Holowaty EJ, Huchcroft SA, Johnston GM, Illing EMM, Mao Y, Semenciw RM: The making of the Canadian cancer registry: cancer incidence in Canada and its regions, 1969 to 1988. Ottawa , Minister of Supply and Services; 1993:Catalogue Number C52-42/1992.

McBride ML, Donaldson L: Ascertainment and data collection for a cancer registry. BC Med J 1987, 29: 30-40.

Lukka H: Prostate cancer: risk categories and role of hormones and radiotherapy. Can J Urol 2002, 9 Suppl 1: 26-29.PubMed

Pepe MS, Mori M: Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993,12(8):737-751. 10.1002/sim.4780120803CrossRef

Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD: A note on competing risks in survival data analysis. Br J Cancer 2004,91(7):1229-1235. 10.1038/sj.bjc.6602102CrossRef

Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ: Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Bmj 2002,325(7367):740. 10.1136/bmj.325.7367.740CrossRef

10.

National Comprehensive Cancer Network (NCCN): National Comprehensive Cancer Network Practice Guidelines in Oncology.[http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf]

11.

Royal College of Radiologists Clinical Oncology Information Network & The British Association of Urological Surgeons: Royal College of Radiologists Guidelines on the Management of Prostate Cancer.[http://www.rcr.ac.uk/docs/oncology/other/prostate.htm]

12.

Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD: Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol 2003,21(17):3318-3327. 10.1200/JCO.2003.09.034CrossRef

13.

Post PN, Hansen BE, Kil PJ, Janssen-Heijnen ML, Coebergh JW: The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population-based study. BJU Int 2001,87(9):821-826. 10.1046/j.1464-410x.2001.02189.xCrossRef

14.

Singh R, O'Brien TS: Comorbidity assessment in localized prostate cancer: a review of currently available techniques. European Urology 2004,46(1):28-41; discussion 41. 10.1016/j.eururo.2004.01.010CrossRef

15.

Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S: An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004, 4: 94. 10.1186/1471-2407-4-94CrossRef

16.

Kastner C, Armitage J, Kimble A, Rawal J, Carter PG, Venn S: The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting. Prostate Cancer Prostatic Dis 9(3):270-4 2006,9(3):270-274. 10.1038/sj.pcan.4500889CrossRef

17.

Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL: Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst 93(23):1822-3 2001,93(23):1822-1823. 10.1093/jnci/93.23.1822CrossRef

Title: The median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancer
Authors: Paul A Blood
Tom Pickles
Publication date: 01-12-2007
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2007
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-2-17

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2007

Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study

What is an acceptably smoothed fluence? Dosimetric and delivery considerations for dynamic sliding window IMRT

Functional intercomparison of intraoperative radiotherapy equipment – Photon Radiosurgery System

Radiosensitization by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide under oxia and hypoxia in human colon cancer cells

Oral Pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study

On the performances of different IMRT treatment planning systems for selected paediatric cases